Leukemia (2013) 27, 251-252; doi:10.1038/leu. 2012.199 Children with Down syndrome (DS) have an increased risk of developing acute myeloid and B-cell precursor acute lymphoblastic leukemia (BCP-ALL). 1 The prognosis of DS ALL is at best similar and often inferior to that of sporadic ALL (non-DS) patients.
2,3 DS ALL is characterized by unique biological features when compared with non-DS ALL. For instance, DS ALL has a lower frequency of the favorable genetic abnormalities t(12;21)(p13;q22) (ETV6-RUNX1) and the unfavorable t(9;22)(q34;q11) (BCR-ABL1), 3,4 but a higher frequency of JAK2 mutations and CRLF2 rearrangements. 5, 6 Using genome-wide screening techniques, several (novel) genomic aberrations involved in the pathogenesis of (non-) DS ALL were identified. 7, 8 The potential prognostic impact of most of these novel aberrations and whether these patients may benefit from specific therapies targeted to these unique genetic features needs to be investigated further.
The B-cell translocation gene 1 (BTG1) was recently described as a recurrent lesion in pediatric BCP-ALL. 7, 9, 10 It was originally identified as a translocation partner of c-MYC in B-cell chronic lymphocytic leukemia. 11, 12 BTG1 is a highly conserved gene and belongs to the family of BTG/TOB genes. 11, 13 It has a role in several crucial cellular processes, such as proliferation, and apoptosis. Recently, Lundin et al.
14 reported on a high frequency of BTG1 deletions (B29%) in DS ALL. However, the study included a limited number of DS ALL patients (n ¼ 17) and hence may not be an accurate estimate of the frequency of BTG1 deletions in DS ALL. Therefore, we investigated the frequency of BTG1 deletions in a large series of DS ALL patients and in addition analyzed the prognostic significance of BTG1 abnormalities.
We screened a population-based cohort of 116 DS ALL patients enrolled in consecutive DCOG and UK treatment protocols (DCOG ALL 8, 9 and 10 and UK ALL ALL97, ALL97/99 and ALL2003). 8 Clinical and cell-biological data, including cytogenetics, were available for all cases. DCOG and UK centrally reviewed diagnosis, classification and clinical follow-up of the patients. The Institutional Review Board approved the investigations, and informed consent was obtained according to local law and regulations.
To identify BTG1 deletions, we performed multiplex ligationdependent probe amplification (MLPA) analysis using the SALSA MLPA kit P335-A3 ALL-IKZF1 (MRC Holland, Amsterdam, the Netherlands), which contains probes for selected B-cell development and differentiation genes. 8 The BTG1 gene is covered by four probes, probes to exon 1, exon 2 and two additional probes localized to the highly conserved promoter region of the gene (area 1 and 2). The full list and location of the MLPA probes can be downloaded from the MRC Holland website (http://www.mrc-holland.com). Peak heights o0.7 (0.75 for MRC UKALL samples) and 41.3 times the control peak height were considered abnormal, with those o0.7 (0.75) representing deletions, and those 41.3 representing duplications. The Kaplan-Meier method was used to estimate the 5-year probability of overall survival (OS), and event-free survival (EFS); survival estimates were compared using the log-rank test. OS was measured from the date of diagnosis to the date of last follow-up or date of death from any cause. EFS was calculated from the date of diagnosis to the date of last follow-up or to the first event, including relapse, failure to achieve complete remission (CR) and death in CR. Cumulative incidence of relapse (CIR) was constructed by the method of Kalbfleisch and Prentice and compared by the Gray test.
All 116 DS ALL patients were classified as B-cell precursor ALL and treated with curative intent. The median age was 5.1 years (range 1.3-23.2), the median WBC was 14 Â 10 9 /l (range 1.2-400) and 65% of the patients were male. The median follow up time for survivors was 4.6 years (range 1.3 months-15.3 years) .
In total, we found 8/116 (6.9%) deletions of BTG1, a frequency lower than described by Lundin et al.
14 in DS ALL and similar to other non-DS B-cell precursor ALL series. 7, 9 Remarkably, all eight patients showed a nearly identical deletion pattern in which the BTG1 area 1, area 2 and exon 2 probes were deleted, whereas exon 1 was retained (6 Â monoallelic, 2 Â biallelic). Due to statistical power, we excluded one patient from the analysis who had a monoallelic amplification of the BTG1 area 2 probe. This patient also had a CRLF2 aberration, but the karyotype of this patient showed no other aberration than the constitutional trisomy 21. She remains in CR for 410 years. The median age of DS ALL patients with a deletion of BTG1 was 5.4 years (range 2.7-23.2), the median WBC was 59 Â 10 9 /l (range 11.3-390) and 62% of the patients were male. This is different from the cohort of Lundin et al., 14 who reported a high median age of 12 years in patients with a BTG1 deletion and a WBC of 25 Â 10 9 /l. Interestingly they reported that BTG1 deletions occurred in predominantly male patients (80%), which is different from our cohort (62% male). BTG1 deletions were not mutually exclusive of other genomic aberrations (for example, IKZF1 in four patients, CRLF2 in four patients). As previously described, 7,9,10 BTG1 deletions were mainly found in patients with ETV6-RUNX1-positive ALL (38% vs 12% in the BTG1 wild-type group; P ¼ 0.02).
Interestingly, BTG1 regulates the glucocorticoid receptor-dependent response in leukemic cells, 15 and it is therefore implicated that loss of this gene perhaps contributes to a poor outcome. 14, 15 Unfortunately, data were available on clinical response to 1 week of prednisone for only two patients with a BTG1 deletion; both were good responders. No significant differences in long-term clinical outcome between wild type and BTG1 deleted cases were detected: 5-year EFS 67 ± 5% vs 60 ± 18% (P ¼ 0.4), OS 72 ± 5% vs 60 ± 18% (P ¼ 0.3), CIR 17 ± 4% vs 15 ± 15% (P(Gray) ¼ 0.9). A stepwise multivariate Cox regression model was performed, which included WBC X50 Â 10 9 , age X10 years and mutational status of BTG1, IKZF1 and ETV6-RUNX1 (Table 1) . Deletions of BTG1 did not predict for prognosis with a hazard ratio (HR) for EFS of 1.97 (95% CI 0.6-6.8); P ¼ 0.29 and OS HR 2.24 (95% CI 0.6-7.9; P ¼ 0.2). Instead, IKZF1 appeared to be the strongest independent risk factor for EFS, with a HR EFS 2.45 (95% CI 1.2-5.1; P ¼ 0.02), as previously described by us. 8 In conclusion, we could not confirm the high frequency of BTG1 deletions as previously described in a small series of DS ALL, but found a prevalence similar to non-DS ALL patients. Moreover, BTG1 deletions did not predict for dismal outcome in DS ALL patients in contrast to IKZF1 aberrations. Further research is needed to identify other potential players and cooperating events in the leukemogenesis in DS children.
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The authors declare no conflict of interest. describing the combination of lenalidomide and R-CHOP in patients with aggressive lymphoma. Our group conducted a similar phase 1b study of this combination in a patient population with predominantly indolent B-cell lymphoma.
The primary objective of the study was to determine the recommended dose of lenalinomide administered for 14 days in association with standard 21-day R-CHOP (R2-CHOP). Dose of lenalidomide was assessed during the first two cycles. Secondary objectives were to assess the safety and efficacy of R2-CHOP for a maximum of six cycles.
Patients from 18 to 70 years of age had documented B-cell CD20-positive lymphoma: mantle cell lymphoma, marginal zone lymphoma, lymphocytic lymphoma, follicular lymphoma, diffuse large B-cell lymphoma or histological transformation from low grade to high grade lymphoma. Lenalidomide (5, 10, 15, 20 or 25 mg once daily) was escalated in serial patient cohorts using a standard 3 þ 3 design. Each cycle of R2-CHOP comprised the Accepted article preview online 26 June 2012; advance online publication, 13 July 2012
